{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T10:11:14Z","timestamp":1789035074780,"version":"build-2803163510"},"reference-count":52,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Carlos Chagas Filho Foundation of Research Support of the State of Rio de Janeiro","award":["FAPERJ #010.101.029\/2018"],"award-info":[{"award-number":["FAPERJ #010.101.029\/2018"]}]},{"name":"Brazilian Council for Scientific Research","award":["CNPq #301744\/2019-0"],"award-info":[{"award-number":["CNPq #301744\/2019-0"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Vaccination remains one of the most successful interventions in medical history [...]<\/jats:p>","DOI":"10.3390\/vaccines14090796","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T09:13:03Z","timestamp":1789031583000},"page":"796","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Advances in Vaccines Against Infectious Diseases"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2172-656X","authenticated-orcid":false,"given":"Salvatore Giovanni","family":"De-Simone","sequence":"first","affiliation":[{"name":"Centro de Desenvolvimento Tecnol\u00f3gico em Sa\u00fade [CDTS], Funda\u00e7\u00e3o Oswaldo Cruz [FIOCRUZ], Rio de Janeiro 21040-900, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1016\/S0140-6736(24)00850-X","article-title":"Contribution of vaccination to improved survival and health: Modelling 50 years of the Expanded Programme on Immunization","volume":"403","author":"Shattock","year":"2024","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Nyasuu, B.J., Heidari, S., Manna, M., Bahl, J., and Goodman, T. (2023). Gender analysis of the World Health Organization online learning program on Immunization Agenda 2030. Front Glob. Womens Health, 4, Erratum in Front Glob. Womens Health. 2024, 5, 1433748. https:\/\/doi.org\/10.3389\/fgwh.2024.1433748.","DOI":"10.3389\/fgwh.2023.1230109"},{"key":"ref_3","unstructured":"World Health Organization (2025). Immunization Agenda 2030: Mid-Term Review, WHO. Available online: https:\/\/www.who.int\/publications\/m\/item\/immunization-agenda-2030--mid-term-review."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"100902","DOI":"10.1016\/S2666-5247(24)00134-4","article-title":"WHO Research agenda for AMR in human health collaborators. WHO global research priorities for antimicrobial resistance in human health","volume":"5","author":"Bertagnolio","year":"2024","journal-title":"Lancet Microbe"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"114142","DOI":"10.1016\/j.addr.2022.114142","article-title":"Toward rational vaccine engineering","volume":"183","author":"Vishweshwaraiah","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.coi.2020.03.013","article-title":"Innovations in structure-based antigen design and immune monitoring for next-generation vaccines","volume":"65","author":"Ward","year":"2020","journal-title":"Curr. Opin. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/s41579-026-01286-y","article-title":"Reverse vaccinology 3.0","volume":"24","author":"Andreano","year":"2026","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.vaccine.2024.06.017","article-title":"The role of vaccines in reducing antimicrobial resistance: A review of potential impact of vaccines on AMR and insights across 16 vaccines and pathogens","volume":"42","author":"Sparrow","year":"2024","journal-title":"Vaccine"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"115419","DOI":"10.1016\/j.addr.2024.115419","article-title":"Advances in the design and delivery of RNA vaccines for infectious diseases","volume":"213","author":"Lokras","year":"2024","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_10","first-page":"123","article-title":"Major findings and recent advances in vaccine development against viral infections using virus-like particles","volume":"34","author":"Mohsen","year":"2017","journal-title":"Vaccines"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"20250012","DOI":"10.1098\/rstb.2025.0012","article-title":"Vaccines and antimicrobial resistance: From science to policy-summary and outcomes","volume":"381","author":"MacLennan","year":"2026","journal-title":"Philos. Trans. R Soc. Lond. B Biol. Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.imlet.2019.10.013","article-title":"Mucosal vaccines: Strategies and challenges","volume":"217","author":"Li","year":"2020","journal-title":"Immunol. Lett."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1016\/S0264-410X(00)00554-5","article-title":"Reverse vaccinology, a genome-based approach to vaccine development","volume":"19","author":"Rappuoli","year":"2001","journal-title":"Vaccine"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"102408","DOI":"10.1016\/j.coi.2023.102408","article-title":"Editorial overview: The march of mucosal vaccines","volume":"86","author":"Lavelle","year":"2024","journal-title":"Curr. Opin. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/s41573-024-01042-y","article-title":"MRNA vaccines for infectious diseases\u2014Advances, challenges and opportunities","volume":"23","author":"Pardi","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41573-021-00283-5","article-title":"MRNA vaccines for infectious diseases: Principles, delivery and clinical translation","volume":"20","author":"Chaudhary","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines\u2014A new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_18","first-page":"111","article-title":"Messenger RNA-based vaccines against infectious diseases","volume":"440","author":"Alameh","year":"2022","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/j.immuni.2022.10.014","article-title":"Innate immune mechanisms of mRNA vaccines","volume":"55","author":"Verbeke","year":"2022","journal-title":"Immunity"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Florek, K., and Sokolski, M. (2024). Myocarditis Associated with COVID-19 Vaccination. Vaccines, 12.","DOI":"10.3390\/vaccines12101193"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"eade2798","DOI":"10.1126\/sciimmunol.ade2798","article-title":"Class switch toward noninflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination","volume":"8","author":"Irrgang","year":"2023","journal-title":"Sci. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/s41591-024-03278-y","article-title":"SARS-CoV-2-specific plasma cells are not durably established in the bone marrow long-lived compartment after mRNA vaccination","volume":"31","author":"Nguyen","year":"2025","journal-title":"Nat. Med."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Blakney, A.K., Ip, S., and Geall, A.J. (2021). An update on self-amplifying mRNA vaccine development. Vaccines, 9.","DOI":"10.3390\/vaccines9020097"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Masignani, V., Pizza, M., and Moxon, E.R. (2019). The development of a vaccine against meningococcus B using reverse vaccinology. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.00751"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"5171","DOI":"10.1016\/j.cell.2024.07.021","article-title":"Transforming vaccinology","volume":"187","author":"Rappuoli","year":"2024","journal-title":"Cell"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"De-Simone, S.G., Lechuga, G.C., Napole\u00e3o-Pego, P., Freitas, M.S., Cardoso, S.V., Morel, C.M., Provance, D.W., and Silva, F.R. (2026). Screening Epitopes through comparative analysis of children and murine immune responses to Pertussis Toxin Subunits (S1-S5) induced by whole-cell pertussis vaccination. Vaccines, 14.","DOI":"10.20944\/preprints202602.1259.v1"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"eade6422","DOI":"10.1126\/scitranslmed.ade6422","article-title":"Rational design of a highly immunogenic prefusion-stabilized F glycoprotein antigen for a respiratory syncytial virus vaccine","volume":"15","author":"Che","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/s41573-024-01041-z","article-title":"Advanced technologies for the development of infectious disease vaccines","volume":"23","author":"Gupta","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/14760584.2023.2292204","article-title":"Pre-erythrocytic malaria vaccines: RTS,S, R21, and beyond","volume":"23","author":"Hammershaimb","year":"2024","journal-title":"Expert Rev. Vaccines"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S1473-3099(24)00010-0","article-title":"R21\/Matrix-M malaria vaccine: A vital tool in the arsenal against malaria, not a silver bullet","volume":"24","author":"Ngou","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Wang, W.C., Sayedahmed, E.E., Sambhara, S., and Mittal, S.K. (2022). Progress towards the development of a universal influenza vaccine. Viruses, 14.","DOI":"10.3390\/v14081684"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1016\/j.vaccine.2019.04.055","article-title":"Vaccine adjuvants: Understanding the structure and mechanism of adjuvanticity","volume":"37","author":"Shi","year":"2019","journal-title":"Vaccine"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Yang, J.X., Tseng, J.C., Yu, G.Y., Luo, Y., Huang, C.F., Hong, Y.R., and Chuang, T.H. (2022). Recent Advances in the Development of Toll-like Receptor Agonist-Based Vaccine Adjuvants for Infectious Diseases. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14020423"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.smim.2018.05.001","article-title":"Correlates of adjuvanticity: A review on adjuvants in licensed vaccines","volume":"39","author":"Giudice","year":"2018","journal-title":"Semin. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Wang, P. (2021). Natural and Synthetic Saponins as Vaccine Adjuvants. Vaccines, 9.","DOI":"10.3390\/vaccines9030222"},{"key":"ref_36","first-page":"3877","article-title":"Recent Advances in Nanoparticle-Based Antiretroviral Drug Delivery Systems for HIV Treatment and Prevention: A Comprehensive Review","volume":"20","author":"Shin","year":"2025","journal-title":"Int. J. Nanomed."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"100908","DOI":"10.1016\/j.ijmmb.2025.100908","article-title":"Present and future prospects of vaccines: Protecting humanity against emerging and re-emerging infectious diseases","volume":"56","author":"Gonal","year":"2025","journal-title":"Indian J. Med. Microbiol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e202400596","DOI":"10.1002\/biot.202400596","article-title":"MRNA Vaccines: Design principles, mechanisms, and manufacturing insights from COVID-19 as a model for combating infectious Diseases","volume":"20","author":"Behzadi","year":"2025","journal-title":"Biotechnol. J."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"100766","DOI":"10.1016\/j.nantod.2019.100766","article-title":"Three decades of messenger RNA vaccine development","volume":"28","author":"Verbeke","year":"2019","journal-title":"Nano Today"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12985-025-02645-6","article-title":"Revolutionizing immunization: A comprehensive review of mRNA vaccine technology and applications","volume":"22","author":"Leong","year":"2025","journal-title":"Virol. J."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"eadv5572","DOI":"10.1126\/science.adv5572","article-title":"Precise targeting of HIV broadly neutralizing antibody precursors in humans","volume":"389","author":"Caniels","year":"2025","journal-title":"Science"},{"key":"ref_42","first-page":"717","article-title":"Delivery Systems of mRNA vaccines in the treatment of infectious diseases: From lipid nanoparticles to next-generation platforms","volume":"15","author":"Hsu","year":"2025","journal-title":"Adv. Pharm. Bull."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"eadk9550","DOI":"10.1126\/sciimmunol.adk9550","article-title":"Germline-targeting HIV vaccination induces neutralizing antibodies to the CD4 binding site","volume":"9","author":"Caniels","year":"2024","journal-title":"Sci. Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41591-020-1118-7","article-title":"A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial","volume":"27","author":"Nachbagauer","year":"2021","journal-title":"Nat. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"103998","DOI":"10.1016\/j.cellimm.2019.103998","article-title":"Aging and influenza vaccine-induced immunity","volume":"348","author":"Dugan","year":"2020","journal-title":"Cell. Immunol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"eadq7006","DOI":"10.1126\/sciadv.adq7006","article-title":"Systemic dysregulation and molecular insights into poor influenza vaccine response in the aging population","volume":"10","author":"Kumar","year":"2024","journal-title":"Sci. Adv."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/S1473-3099(24)00497-3","article-title":"Optimising vaccine immunogenicity in aing populations: Key strategies","volume":"25","author":"Jiang","year":"2025","journal-title":"Lancet Infect. Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1038\/s41467-024-45495-6","article-title":"Broad protection against clade 1 sarbecoviruses after a single immunization with cocktail spike-protein-nanoparticle vaccine","volume":"15","author":"Halfmann","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/s41577-024-01030-8","article-title":"Opportunities and challenges for T cell-based influenza vaccines","volume":"24","author":"Mosmann","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41423-023-01116-8","article-title":"In search of a pan-coronavirus vaccine: Next-generation vaccine design and immune mechanisms","volume":"21","author":"Cankat","year":"2024","journal-title":"Cell. Mol. Immunol."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Shinkura, R. (2024). Editorial: Mucosal vaccines for the induction of antimicrobial immunoglobulin A. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1270600"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e1681","DOI":"10.1002\/wnan.1681","article-title":"Advancements in protein nanoparticle vaccine platforms to combat infectious disease","volume":"13","author":"Butkovich","year":"2021","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/9\/796\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T09:37:44Z","timestamp":1789033064000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/9\/796"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":52,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["vaccines14090796"],"URL":"https:\/\/doi.org\/10.3390\/vaccines14090796","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]}}}